Trials / Completed
CompletedNCT04547361
A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2511 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of E2511 following single ascending oral doses in healthy adult and elderly participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2511 | E2511 tablets. |
| DRUG | E2511 Matched Placebo | Placebo tablets matching E2511 tablets. |
Timeline
- Start date
- 2020-09-14
- Primary completion
- 2021-05-26
- Completion
- 2021-05-26
- First posted
- 2020-09-14
- Last updated
- 2021-07-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04547361. Inclusion in this directory is not an endorsement.